Par-4 as a potential target for cancer therapy

Rosalyn Irby, Christina Lb Kline

Research output: Contribution to journalReview article

11 Citations (Scopus)

Abstract

Introduction: Despite extensive research, cancer continues to be a leading cause of death worldwide and is expected to continue to rise as a result of an aging population. Therefore, new therapies are constantly being developed. Par-4 is a naturally occurring tumor suppressor protein that is capable of inducing apoptosis in cancer, but not normal cells. For this reason, Par-4 offers an attractive target for development of cancer therapy, particularly of difficult to treat cancers. Areas covered: The mechanisms by which Par-4 induces cell death are summarized. The ways that Par-4 is controlled in cancer cells are discussed. We discuss how different research groups have developed ways to overexpress and/or activate Par-4 in vitro and in vivo. The studies described demonstrate that when Par-4 levels and/or activity are increased, susceptibility to apoptosis is enhanced and tumor growth is inhibited. Expert opinion: Par-4 is a promising therapeutic protein that can be overexpressed and/or activated to induce apoptosis in a cancer-selective manner. This cancer selectivity is important given that the side-effects of chemotherapeutics can be as debilitating as cancer itself. However, there are key issues that need to be addressed to optimize the effects of Par-4 in patients.

Original languageEnglish (US)
Pages (from-to)77-87
Number of pages11
JournalExpert Opinion on Therapeutic Targets
Volume17
Issue number1
DOIs
StatePublished - Jan 1 2013

Fingerprint

Apoptosis
Tumor Suppressor Proteins
Neoplasms
Cell death
Tumors
Therapeutics
Aging of materials
Cells
Proteins
Expert Testimony
Research
Cause of Death
Cell Death
Growth
Population

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cite this

Irby, Rosalyn ; Kline, Christina Lb. / Par-4 as a potential target for cancer therapy. In: Expert Opinion on Therapeutic Targets. 2013 ; Vol. 17, No. 1. pp. 77-87.
@article{be948f18760e453c88cbb63daa052e0d,
title = "Par-4 as a potential target for cancer therapy",
abstract = "Introduction: Despite extensive research, cancer continues to be a leading cause of death worldwide and is expected to continue to rise as a result of an aging population. Therefore, new therapies are constantly being developed. Par-4 is a naturally occurring tumor suppressor protein that is capable of inducing apoptosis in cancer, but not normal cells. For this reason, Par-4 offers an attractive target for development of cancer therapy, particularly of difficult to treat cancers. Areas covered: The mechanisms by which Par-4 induces cell death are summarized. The ways that Par-4 is controlled in cancer cells are discussed. We discuss how different research groups have developed ways to overexpress and/or activate Par-4 in vitro and in vivo. The studies described demonstrate that when Par-4 levels and/or activity are increased, susceptibility to apoptosis is enhanced and tumor growth is inhibited. Expert opinion: Par-4 is a promising therapeutic protein that can be overexpressed and/or activated to induce apoptosis in a cancer-selective manner. This cancer selectivity is important given that the side-effects of chemotherapeutics can be as debilitating as cancer itself. However, there are key issues that need to be addressed to optimize the effects of Par-4 in patients.",
author = "Rosalyn Irby and Kline, {Christina Lb}",
year = "2013",
month = "1",
day = "1",
doi = "10.1517/14728222.2013.731047",
language = "English (US)",
volume = "17",
pages = "77--87",
journal = "Expert Opinion on Therapeutic Targets",
issn = "1472-8222",
publisher = "Informa Healthcare",
number = "1",

}

Par-4 as a potential target for cancer therapy. / Irby, Rosalyn; Kline, Christina Lb.

In: Expert Opinion on Therapeutic Targets, Vol. 17, No. 1, 01.01.2013, p. 77-87.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Par-4 as a potential target for cancer therapy

AU - Irby, Rosalyn

AU - Kline, Christina Lb

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Introduction: Despite extensive research, cancer continues to be a leading cause of death worldwide and is expected to continue to rise as a result of an aging population. Therefore, new therapies are constantly being developed. Par-4 is a naturally occurring tumor suppressor protein that is capable of inducing apoptosis in cancer, but not normal cells. For this reason, Par-4 offers an attractive target for development of cancer therapy, particularly of difficult to treat cancers. Areas covered: The mechanisms by which Par-4 induces cell death are summarized. The ways that Par-4 is controlled in cancer cells are discussed. We discuss how different research groups have developed ways to overexpress and/or activate Par-4 in vitro and in vivo. The studies described demonstrate that when Par-4 levels and/or activity are increased, susceptibility to apoptosis is enhanced and tumor growth is inhibited. Expert opinion: Par-4 is a promising therapeutic protein that can be overexpressed and/or activated to induce apoptosis in a cancer-selective manner. This cancer selectivity is important given that the side-effects of chemotherapeutics can be as debilitating as cancer itself. However, there are key issues that need to be addressed to optimize the effects of Par-4 in patients.

AB - Introduction: Despite extensive research, cancer continues to be a leading cause of death worldwide and is expected to continue to rise as a result of an aging population. Therefore, new therapies are constantly being developed. Par-4 is a naturally occurring tumor suppressor protein that is capable of inducing apoptosis in cancer, but not normal cells. For this reason, Par-4 offers an attractive target for development of cancer therapy, particularly of difficult to treat cancers. Areas covered: The mechanisms by which Par-4 induces cell death are summarized. The ways that Par-4 is controlled in cancer cells are discussed. We discuss how different research groups have developed ways to overexpress and/or activate Par-4 in vitro and in vivo. The studies described demonstrate that when Par-4 levels and/or activity are increased, susceptibility to apoptosis is enhanced and tumor growth is inhibited. Expert opinion: Par-4 is a promising therapeutic protein that can be overexpressed and/or activated to induce apoptosis in a cancer-selective manner. This cancer selectivity is important given that the side-effects of chemotherapeutics can be as debilitating as cancer itself. However, there are key issues that need to be addressed to optimize the effects of Par-4 in patients.

UR - http://www.scopus.com/inward/record.url?scp=84871192322&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871192322&partnerID=8YFLogxK

U2 - 10.1517/14728222.2013.731047

DO - 10.1517/14728222.2013.731047

M3 - Review article

C2 - 23062118

AN - SCOPUS:84871192322

VL - 17

SP - 77

EP - 87

JO - Expert Opinion on Therapeutic Targets

JF - Expert Opinion on Therapeutic Targets

SN - 1472-8222

IS - 1

ER -